How Much Weight Loss is Effective on Nonalcoholic Fatty Liver Disease?

Overview

Journal Hepat Mon

Publisher Brieflands

Specialty Gastroenterology

Date 2013 Dec 21

PMID 24358045

Citations 23

Authors

Alireza Ghaemi

Fourugh Azam Taleban

Azita Hekmatdoost

Alireza Rafiei

Vahid Hosseini

Zohreh Amiri

Reza Homayounfar

Hafez Fakheri

Affiliations

Soon will be listed here.

Abstract

Background: Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide with no specific treatment. Weight loss is the most effective therapeutic strategy in its management; however, there is no consensus on its specifics. Thus, this study was conducted to evaluate the effects of weight loss on liver enzymes, markers of inflammation, oxidative stress and CK18-M30 (cytokeratin 18) as a biomarker of hepatocellular apoptosis.

Objectives: To study the effect of weight reduction diet as an exclusive treatment for NAFLD.

Patients And Methods: Forty four patients with NAFLD received a diet including a 500 to 1000 kcal per day intake reduction as30% fat, 15% protein, and 55% carbohydrate for six months. Anthropometric parameters, alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma glutamyl transferase (GGT), lipid profile, malondialdehyde (MDA), TNF-α, IL-6, CK18-M30 were measured at baseline and at the end of the study. At the end of follow up, patients were classified as adherent or nonadherent to treatment according to a weight loss of ≥ 5%, or < 5% of initial body weight, respectively.

Results: Twenty five patients were classified as adherent group and nineteen as nonadherent group (9.7% vs. 1.9% total body weight loss after 6 months, respectively). After 6 months, changes in adherent and nonadherent groups were as follows: reduction in body weight from 93.7 ± 15.8 kg to 84.2 ± 13.4 kg vs. 94 ± 16.6 kg to 92.2 ± 16.2 kg (P < 0.05), BMI from 32.7 ± 3.9 to 29.5 ± 3.2 vs.31.8 ± 5.4 to 31.1 ± 5.3 (P < 0.001), and waist circumference from 105.1 ± 12.6 cm to 97.4 ± 9.8 cm vs.106.8 ± 14.2 cm to 103.7 ± 14 cm (P < 0.001), respectively. Diastolic blood pressure was significantly decreased in adherent group (from 80.2 ± 5.1 mmHg to 76.9 ± 5 mmHg; P < 0.001). Also, total cholesterol, LDL, triglyceride, ALT, AST, GGT and CK18-M30 levels were significantly decreased in the adherent group compared to nonadherent group (P < 0.05).

Conclusions: This intervention offers a practical approach for treatment of patients with NAFLD with diet therapy.

Citing Articles

Liver Fibrosis and Cirrhosis in Patients with Non-alcoholic Fatty Liver with and without History of Cholecystectomy: A Pilot Study.

Parsi A, Hajiani E, Sadani S, Hashemi S, Seyedian S, Alimadadi M Middle East J Dig Dis. 2024; 16(1):34-38.

PMID: 39050095 PMC: 11264833. DOI: 10.34172/mejdd.2024.366.

A Novel Foodstuff Mixture Improves the Gut-Liver Axis in MASLD Mice and the Gut Microbiota in Overweight/Obese Patients.

Rosas-Campos R, Sandoval-Rodriguez A, Rodriguez-Sanabria J, Vazquez-Esqueda A, Alfaro-Martinez C, Escutia-Gutierrez R Antioxidants (Basel). 2024; 13(6).

PMID: 38929103 PMC: 11200377. DOI: 10.3390/antiox13060664.

Development and Validation of a Questionnaire to Assess Awareness and Knowledge of Nonalcoholic Fatty Liver Disease, a Liver Cancer Etiological Factor, among Chinese Young Adults.

Du Y, Rochling F, Su D, Ratnapradipa K, Dong J, Farazi P Asian Pac J Cancer Prev. 2023; 24(5):1543-1551.

PMID: 37247273 PMC: 10495908. DOI: 10.31557/APJCP.2023.24.5.1543.

Effect of a moderately carbohydrate-restricted diet on liver enzymes, steatosis and fibrosis in normal-weight individuals with non-alcoholic fatty liver disease: study protocol for a parallel randomised controlled clinical trial.

Dashti F, Alavian S, Sohrabpour A, Mousavi S, Keshavarz S, Esmaillzadeh A BMJ Open. 2023; 13(4):e063988.

PMID: 37117000 PMC: 10151946. DOI: 10.1136/bmjopen-2022-063988.

Effects of Calorie Restricted Diet on Oxidative/Antioxidative Status Biomarkers and Serum Fibroblast Growth Factor 21 Levels in Nonalcoholic Fatty Liver Disease Patients: A Randomized, Controlled Clinical Trial.

Asghari S, Rezaei M, Rafraf M, Taghizadeh M, Asghari-Jafarabadi M, Ebadi M Nutrients. 2022; 14(12).

PMID: 35745238 PMC: 9231395. DOI: 10.3390/nu14122509.

References

Madan K, Bhardwaj P, Thareja S, Gupta S, Saraya A . Oxidant stress and antioxidant status among patients with nonalcoholic fatty liver disease (NAFLD). J Clin Gastroenterol. 2006; 40(10):930-5. DOI: 10.1097/01.mcg.0000212608.59090.08. View

Merriam P, Ma Y, Olendzki B, Schneider K, Li W, Ockene I . Design and methods for testing a simple dietary message to improve weight loss and dietary quality. BMC Med Res Methodol. 2010; 9:87. PMC: 2811706. DOI: 10.1186/1471-2288-9-87. View

Ghamar Chehreh M, Vahedi M, Pourhoseingholi M, Ashtari S, Khedmat H, Amin M . Estimation of diagnosis and treatment costs of non-alcoholic Fatty liver disease: a two-year observation. Hepat Mon. 2013; 13(5):e7382. PMC: 3728974. DOI: 10.5812/hepatmon.7382. View

Rebollo A, Roglans N, Alegret M, Laguna J . Way back for fructose and liver metabolism: bench side to molecular insights. World J Gastroenterol. 2012; 18(45):6552-9. PMC: 3516224. DOI: 10.3748/wjg.v18.i45.6552. View

Hickman I, Jonsson J, Prins J, Ash S, Purdie D, Clouston A . Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut. 2004; 53(3):413-9. PMC: 1773957. DOI: 10.1136/gut.2003.027581. View

Jamali R, Khonsari M, Merat S, Khoshnia M, Jafari E, Bahram Kalhori A . Persistent alanine aminotransferase elevation among the general Iranian population: prevalence and causes. World J Gastroenterol. 2008; 14(18):2867-71. PMC: 2710729. DOI: 10.3748/wjg.14.2867. View

Tabuchi M, Tomioka K, Kawakami T, Murakami Y, Hiramatsu M, Itoshima T . Serum cytokeratin 18 M30 antigen level and its correlation with nutritional parameters in middle-aged Japanese males with nonalcoholic fatty liver disease (NAFLD). J Nutr Sci Vitaminol (Tokyo). 2011; 56(5):271-8. DOI: 10.3177/jnsv.56.271. View

Browning J, Szczepaniak L, Dobbins R, Nuremberg P, Horton J, Cohen J . Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004; 40(6):1387-95. DOI: 10.1002/hep.20466. View

Baumeister S, Volzke H, Marschall P, John U, Schmidt C, Flessa S . Impact of fatty liver disease on health care utilization and costs in a general population: a 5-year observation. Gastroenterology. 2007; 134(1):85-94. DOI: 10.1053/j.gastro.2007.10.024. View

10.

Zelber-Sagi S, Ratziu V, Oren R . Nutrition and physical activity in NAFLD: an overview of the epidemiological evidence. World J Gastroenterol. 2011; 17(29):3377-89. PMC: 3160564. DOI: 10.3748/wjg.v17.i29.3377. View

11.

Vuppalanchi R, Chalasani N . Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology. 2008; 49(1):306-17. PMC: 2766096. DOI: 10.1002/hep.22603. View

12.

Malhi H, Bronk S, Werneburg N, Gores G . Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis. J Biol Chem. 2006; 281(17):12093-101. DOI: 10.1074/jbc.M510660200. View

13.

Younossi Z, Page S, Rafiq N, Birerdinc A, Stepanova M, Hossain N . A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis. Obes Surg. 2010; 21(4):431-9. DOI: 10.1007/s11695-010-0204-1. View

14.

Rolo A, Teodoro J, Palmeira C . Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radic Biol Med. 2011; 52(1):59-69. DOI: 10.1016/j.freeradbiomed.2011.10.003. View

15.

Tamimi T, Elgouhari H, Alkhouri N, Yerian L, Berk M, Lopez R . An apoptosis panel for nonalcoholic steatohepatitis diagnosis. J Hepatol. 2010; 54(6):1224-9. PMC: 3098936. DOI: 10.1016/j.jhep.2010.08.023. View

16.

Bagheri Lankarani K, Ghaffarpasand F, Mahmoodi M, Lotfi M, Zamiri N, Heydari S . Non alcoholic fatty liver disease in southern Iran: a population based study. Hepat Mon. 2013; 13(5):e9248. PMC: 3734894. DOI: 10.5812/hepatmon.9248. View

17.

Festi D, Colecchia A, Sacco T, Bondi M, Roda E, Marchesini G . Hepatic steatosis in obese patients: clinical aspects and prognostic significance. Obes Rev. 2004; 5(1):27-42. DOI: 10.1111/j.1467-789x.2004.00126.x. View

18.

Assy N . Nutritional recommendations for patients with non-alcoholic fatty liver diseases. World J Gastroenterol. 2011; 17(29):3375-6. PMC: 3160563. DOI: 10.3748/wjg.v17.i29.3375. View

19.

Mensink R, Plat J, Schrauwen P . Diet and nonalcoholic fatty liver disease. Curr Opin Lipidol. 2008; 19(1):25-9. DOI: 10.1097/MOL.0b013e3282f382ea. View

20.

Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G . A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol. 2010; 53(2):372-84. DOI: 10.1016/j.jhep.2010.04.008. View